Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on Salesforce, Lowers Price Target to $200

Baird Maintains Outperform on Salesforce, Lowers Price Target to $200

Baird analyst Rob Oliver maintains Salesforce (NYSE:CRM) with a Outperform and lowers the price target from $210 to $200.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Baird analyst Rob Oliver maintains Salesforce (NYSE:CRM) with a Outperform and lowers the price target from $210 to $200.

Analyst Ratings

Where Pactiv Evergreen Stands With Analysts

By Benzinga Insights

Yesterday, 3:01 PM

Ratings for Pactiv Evergreen (NASDAQ:PTVE) were provided by 8 analysts in the past three months, showcasing a mix…

PTVE

Rhythm Pharmaceuticals Q4 EPS $(0.75) Beats $(0.81) Estimate, Sales $8.79 Miss $7.03M Estimate

By Benzinga Newsdesk

March 1, 8:01 AM

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.85) per share

RYTM

$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today

By Benzinga Insights

February 21, 3:03 PM

Chipotle Mexican Grill (NYSE:CMG) has outperformed the market over the past 5 years by 30.61% on an annualized…

CMG

Keybanc Maintains Overweight on Box, Raises Price Target to $37

By Benzinga Newsdesk

January 18, 5:33 AM

Keybanc analyst Thomas Blakey maintains Box (NYSE:BOX) with a Overweight and raises the price target from $34 to $37.

BOX

Baird Maintains Outperform on Salesforce, Lowers Price Target to $200

Related Posts

Where Pactiv Evergreen Stands With Analysts

Rhythm Pharmaceuticals Q4 EPS $(0.75) Beats $(0.81) Estimate, Sales $8.79 Miss $7.03M Estimate

$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today

Keybanc Maintains Overweight on Box, Raises Price Target to $37